Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Clearside Biomedical Inc. has 3 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 3 distinct examiners across 2 distinct art units, showing examiner-level dispersion within a narrower technical-unit structure.
BARSKY, JARED is the busiest examiner, with 1 pending matter. Counsel should coordinate around the shared art-unit context while preserving separate examiner-specific response plans.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BARSKY, JARED | 1 | 50.3% | +22.8% |
| PECKHAM, RICHARD GRANT | 1 | 68.1% | +36.1% |
| HUI, SAN MING R | 1 | 59.6% | +20.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18776683 | COMPOSITIONS COMPRISING AXITINIB AND METHODS OF TREATING OCULAR DISORDERS | BARSKY, JARED | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18776683 | COMPOSITIONS COMPRISING AXITINIB AND METHODS OF TREATING OCULAR DISORDERS | BARSKY, JARED | — |
| 18726889 | COMPOSITIONS AND METHODS FOR TREATING MACULAR EDEMA ASSOCIATED WITH UVEITIS | PECKHAM, RICHARD GRANT | — |
| 17478112 | COMPOSITIONS AND METHODS FOR TREATING NONINFECTIOUS UVEITIS | HUI, SAN MING R | — |
| Art Unit | Apps |
|---|---|
| 1627 | 2 |
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18776683 | COMPOSITIONS COMPRISING AXITINIB AND METHODS OF TREATING OCULAR DISORDERS | BARSKY, JARED | 1628 | §102§103Other | Non-Final OA | — | Pending | Jul 18, 2024 |
| 18726889 | COMPOSITIONS AND METHODS FOR TREATING MACULAR EDEMA ASSOCIATED WITH UVEITIS | PECKHAM, RICHARD GRANT | 1627 | §102§103§112DP | Non-Final OA | — | Pending | Jul 05, 2024 |
| 17478112 | COMPOSITIONS AND METHODS FOR TREATING NONINFECTIOUS UVEITIS | HUI, SAN MING R | 1627 | §103 | Non-Final OA | — | Pending | Sep 17, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialClearside Biomedical Inc. has 3 pending office actions as of October 2026, spread across 2 art units and 3 examiners.
Jared Barsky has the most, with 1 of Clearside Biomedical Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
